

Philippe Marambaud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6694135/publications.pdf>

Version: 2024-02-01

80
papers

15,074
citations

87843

38
h-index

69214

77
g-index

94
all docs

94
docs citations

94
times ranked

27685
citing authors

#	ARTICLE	IF	CITATIONS
1	Extracellular CIRP Activates the IL-6R \pm /STAT3/Cdk5 Pathway in Neurons. <i>Molecular Neurobiology</i> , 2021, 58, 3628-3640.	1.9	10
2	Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models. <i>Acta Neuropathologica Communications</i> , 2020, 8, 126.	2.4	5
3	Molecular and Pharmacological Modulation of CALHM1 Promote Neuroprotection against Oxygen and Glucose Deprivation in a Model of Hippocampal Slices. <i>Cells</i> , 2020, 9, 664.	1.8	11
4	Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models. <i>Journal of Clinical Investigation</i> , 2020, 130, 942-957.	3.9	48
5	Blockade and knock-out of CALHM1 channels attenuate ischemic brain damage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1060-1069.	2.4	9
6	Chemical synapses without synaptic vesicles: Purinergic neurotransmission through a CALHM1 channel-mitochondrial signaling complex. <i>Science Signaling</i> , 2018, 11, .	1.6	69
7	Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. <i>Acta Neuropathologica Communications</i> , 2018, 6, 82.	2.4	34
8	Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology. <i>Human Molecular Genetics</i> , 2017, 26, 4786-4798.	1.4	45
9	CALHM1-Mediated ATP Release and Ciliary Beat Frequency Modulation in Nasal Epithelial Cells. <i>Scientific Reports</i> , 2017, 7, 6687.	1.6	34
10	A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate A β ² Peptides. <i>Molecular Medicine</i> , 2016, 22, 841-849.	1.9	7
11	ERK1/2 activation in human taste bud cells regulates fatty acid signaling and gustatory perception of fat in mice and humans. <i>FASEB Journal</i> , 2016, 30, 3489-3500.	0.2	30
12	CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice. <i>Scientific Reports</i> , 2016, 6, 24250.	1.6	30
13	AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. <i>Scientific Reports</i> , 2016, 6, 26758.	1.6	95
14	Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 121-130.	1.8	23
15	A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10. <i>Scientific Reports</i> , 2016, 6, 37366.	1.6	44
16	Pomalidomide reverses β -globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. <i>Blood</i> , 2016, 127, 1481-1492.	0.6	75
17	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
18	Stimulation of Brain AMP-Activated Protein Kinase Attenuates Inflammation and Acute Lung Injury in Sepsis. <i>Molecular Medicine</i> , 2015, 21, 637-644.	1.9	22

#	ARTICLE	IF	CITATIONS
19	CALHM1 ion channel elicits amyloid- β^2 clearance by insulin-degrading enzyme in cell lines and <i>in vivo</i> in the mouse brain. <i>Journal of Cell Science</i> , 2015, 128, 2330-2338.	1.2	32
20	CALHM1 Deletion in Mice Affects Glossopharyngeal Taste Responses, Food Intake, Body Weight, and Life Span. <i>Chemical Senses</i> , 2015, 40, 373-379.	1.1	10
21	Novel resveratrol analogues attenuate renal ischemic injury in rats. <i>Journal of Surgical Research</i> , 2015, 193, 807-815.	0.8	11
22	Pomalidomide Transcriptionally Reprograms Adult Erythroid Progenitors Independently of Ikaros Proteasomal Degradation. <i>Blood</i> , 2015, 126, 160-160.	0.6	1
23	Effect of the CALHM1 G330D and R154H Human Variants on the Control of Cytosolic Ca ²⁺ and A β^2 Levels. <i>PLoS ONE</i> , 2014, 9, e112484.	1.1	11
24	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. <i>Molecular Medicine</i> , 2014, 20, 29-36.	1.9	55
25	Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid β^2 . <i>Journal of Neuroscience</i> , 2014, 34, 12230-12238.	1.7	143
26	Salty Taste Deficits in CALHM1 Knockout Mice. <i>Chemical Senses</i> , 2014, 39, 515-528.	1.1	38
27	Sucrose-conditioned flavor preferences in sweet ageusia T1r3 and Calhm1 knockout mice. <i>Physiology and Behavior</i> , 2014, 126, 25-29.	1.0	34
28	Overexpression of Extracellular Superoxide Dismutase Protects against Brain Injury Induced by Chronic Hypoxia. <i>PLoS ONE</i> , 2014, 9, e108168.	1.1	24
29	Calcium Homeostasis Modulator (CALHM) Ion Channels: Structure, Functions and Physiological Roles. <i>Membrane</i> , 2014, 39, 41-47.	0.0	0
30	How do taste cells lacking synapses mediate neurotransmission? CALHM1, a voltage-gated ATP channel. <i>BioEssays</i> , 2013, 35, 1111-1118.	1.2	66
31	CALHM1 controls the Ca ²⁺ -dependent MEK, ERK, RSK and MSK signaling cascade in neurons. <i>Journal of Cell Science</i> , 2013, 126, 1199-1206.	1.2	35
32	CALHM1 Ion Channel Mediates Purinergic Neurotransmission from Taste Buds to Gustatory Nerve Terminals during Sweet and Bitter Perception. <i>Biophysical Journal</i> , 2013, 104, 631a.	0.2	0
33	CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. <i>Nature</i> , 2013, 495, 223-226.	13.7	405
34	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. <i>Molecular Medicine</i> , 2013, 19, 29-36.	1.9	22
35	Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca ²⁺ regulation of neuronal excitability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1963-71.	3.3	132
36	Identification of potent small molecule inhibitors of STAT3 with anti-inflammatory properties in RAW264.7 macrophages. <i>FEBS Journal</i> , 2012, 279, 3791-3799.	2.2	29

#	ARTICLE	IF	CITATIONS
37	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
38	Gas1 Interferes with A β PP Trafficking by Facilitating the Accumulation of Immature A β PP in Endoplasmic Reticulum-Associated Raft Subdomains. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 127-135.	1.2	2
39	Identification and biology of Î²-secretase. <i>Journal of Neurochemistry</i> , 2012, 120, 34-45.	2.1	77
40	Resveratrol mitigates lipopolysaccharide- and A β -mediated microglial inflammation by inhibiting the TLR4/NF- κ B/STAT signaling cascade. <i>Journal of Neurochemistry</i> , 2012, 120, 461-472.	2.1	363
41	Overexpression of extracellular superoxide dismutase has a protective role against hyperoxia-induced brain injury in neonatal mice. <i>FEBS Journal</i> , 2012, 279, 871-881.	2.2	26
42	CALHM1 P86L Polymorphism Modulates CSF A β Levels in Cognitively Healthy Individuals at Risk for Alzheimer's Disease. <i>Molecular Medicine</i> , 2011, 17, 974-979.	1.9	26
43	Small-Molecule Activators of AMP-Activated Protein Kinase (AMPK), RSVA314 and RSVA405, Inhibit Adipogenesis. <i>Molecular Medicine</i> , 2011, 17, 1022-1030.	1.9	75
44	Neuroprotective and metabolic effects of resveratrol: Therapeutic implications for Huntington's disease and other neurodegenerative disorders. <i>Experimental Neurology</i> , 2011, 232, 1-6.	2.0	81
45	AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. <i>Acta Neuropathologica</i> , 2011, 121, 337-349.	3.9	247
46	Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid- β peptide degradation. <i>FASEB Journal</i> , 2011, 25, 219-231.	0.2	209
47	Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid- β precursor protein. <i>Human Molecular Genetics</i> , 2011, 20, 2026-2036.	1.4	15
48	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 247-255.	1.2	54
49	AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid- β Peptide Metabolism. <i>Journal of Biological Chemistry</i> , 2010, 285, 9100-9113.	1.6	560
50	Letter to the Editor on Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 400, 452.	1.0	1
51	Calcium signaling in neurodegeneration. <i>Molecular Neurodegeneration</i> , 2009, 4, 20.	4.4	258
52	Amyloid-beta peptide degradation in cell cultures by mycoplasma contaminants. <i>BMC Research Notes</i> , 2008, 1, 38.	0.6	28
53	A Polymorphism in CALHM1 Influences Ca ²⁺ Homeostasis, A β Levels, and Alzheimer's Disease Risk. <i>Cell</i> , 2008, 133, 1149-1161.	13.5	310
54	Response: CALHM1 Association with Alzheimer's Disease Risk. <i>Cell</i> , 2008, 135, 994-996.	13.5	25

#	ARTICLE	IF	CITATIONS
55	Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neuroscience, 2008, 9, S6.	0.8	178
56	CNI-1493 inhibits A β production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. Journal of Experimental Medicine, 2008, 205, 1593-1599.	4.2	21
57	CNI-1493 inhibits A β production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. Journal of Cell Biology, 2008, 182, i1-i1.	2.3	0
58	Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiology of Disease, 2007, 25, 686-696.	2.1	78
59	The Presenilin-1 Secretase Complex Regulates Production of Transcriptional Factors: Effects of FAD Mutations. , 2006, , 398-416.		0
60	The cytoplasmic sequence of E-cadherin promotes non-amyloidogenic degradation of Abeta precursors. Journal of Neurochemistry, 2006, 96, 1182-1188.	2.1	17
61	TMP21 is a presenilin complex component that modulates β -secretase but not γ -secretase activity. Nature, 2006, 440, 1208-1212.	13.7	286
62	Role of peroxisome proliferator-activated receptor δ in amyloid precursor protein processing and amyloid β -mediated cell death. Biochemical Journal, 2005, 391, 693-698.	1.7	78
63	JLK Inhibitors: Isocoumarin Compounds as Putative Probes to Selectively Target the γ -Secretase Pathway. Current Alzheimer Research, 2005, 2, 327-334.	0.7	10
64	Resveratrol Promotes Clearance of Alzheimer's Disease Amyloid- β Peptides. Journal of Biological Chemistry, 2005, 280, 37377-37382.	1.6	669
65	O3-05-02 FAD-linked presenilin-1 mutations affect the N-cadherin/CBP signaling pathway via a loss-of-function mechanism. Neurobiology of Aging, 2004, 25, S61-S62.	1.5	2
66	A CBP Binding Transcriptional Repressor Produced by the PS1/ μ -Cleavage of N-Cadherin Is Inhibited by PS1 FAD Mutations. Cell, 2003, 114, 635-645.	13.5	459
67	Métabolisme du précurseur du peptide amyloïde et des α -nilines. Medecine/Sciences, 2002, 18, 717-724.		0
68	A presenilin-1/ γ -secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO Journal, 2002, 21, 1948-1956.	3.5	621
69	Role of the proteasome in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 133-138.	1.8	89
70	Presenilin-1: A Component of Synaptic and Endothelial Adherens Junctions. Annals of the New York Academy of Sciences, 2000, 920, 209-214.	1.8	13
71	Presenilin-1 Forms Complexes with the Cadherin/Catenin Cell-Cell Adhesion System and Is Recruited to Intercellular and Synaptic Contacts. Molecular Cell, 1999, 4, 893-902.	4.5	221
72	Proteasome Inhibitors Prevent the Degradation of Familial Alzheimer's Disease-Linked Presenilin 1 and Potentiate A β Recovery from Human Cells. Molecular Medicine, 1998, 4, 147-157.	1.9	67

#	ARTICLE	IF	CITATIONS
73	Characterization of New Polyclonal Antibodies Specific for 40 and 42 Amino Acid-Long Amyloid β Peptides: Their Use to Examine the Cell Biology of Presenilins and the Immunohistochemistry of Sporadic Alzheimer's Disease and Cerebral Amyloid Angiopathy Cases. <i>Molecular Medicine</i> , 1997, 3, 695-707.	1.9	142
74	Cathepsin D displays in vitro β -secretase-like specificity. <i>Brain Research</i> , 1997, 750, 11-19.	1.1	94
75	Proteasome Contributes to the β -Secretase Pathway of Amyloid Precursor Protein in Human Cells. <i>Journal of Neurochemistry</i> , 1997, 68, 698-703.	2.1	48
76	β -Secretase-Derived Product of β -Amyloid Precursor Protein Is Decreased by Presenilin 1 Mutations Linked to Familial Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1997, 69, 2494-2499.	2.1	63
77	Constitutive and Protein Kinase C-Regulated Secretory Cleavage of Alzheimer's β -Amyloid Precursor Protein: Different Control of Early and Late Events by the Proteasome. <i>Journal of Neurochemistry</i> , 1997, 69, 2500-2505.	2.1	41
78	Contribution of the Proteasome to the β -Secretase Pathway in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 1997, 421, 267-272.	0.8	5
79	Protein Kinase A Phosphorylation of the Proteasome: A Contribution to the β -Secretase Pathway in Human Cells. <i>Journal of Neurochemistry</i> , 1996, 67, 2616-2619.	2.1	36
80	Presenilin-1 is a Regulatory Component of the Cadherin Cell Adhesion Complex: Implications for Alzheimer's Disease. , 0, , 521-530.		1